Loading patent…
AssigneesKansai Technology Licensing Organization Co., Ltd., Japan Immunoresearch Laboratories Co., Ltd.
InventorsSusumu Ikehara, Yasushi Adachi, Yasuhiro Suzuki
Estimating the term…
The invention provides a technology which utilizes donor lymphocyte infusion and by which malignant tumor can be treated without causing such an adverse effect as graft versus host disease. Thus, a method for the treatment of malignant tumor is provided which comprises performing, in a patient requiring such treatment, donor lymphocyte infusion for the graft versus tumor reaction-based treatment of tumor and then performing radiation treatment, infusion of lymphocytes derived from the host or a third party identical in HLA type to the host, and intra bone marrow-bone marrow transplantation using bone marrow cells derived from the host or a third party identical in HLA type to the host, for the prevention and treatment of the graft versus host disease induced by the donor lymphocyte infusion.
A method for the treatment of malignant tumor which comprises performing donor leukocyte infusion in a patient requiring such treatment and then performing radiation treatment (irradiation), infusion of lymphocytes derived from the host or a third party identical in HLA type to the host, and intra bone marrow-bone marrow transplantation using bone marrow cells derived from the host or a third party identical in HLA type to the host.
A method for the treatment of malignant tumor which comprises performing donor lymphocyte infusion for graft versus tumor reaction-based tumor treatment in a patient to be treated and then performing radiation treatment and intravenous administration of peripheral blood stem cells derived from the host or a third party identical in HLA type to the host for the prevention and treatment of the graft versus host disease caused by said donor lymphocyte infusion.
A method for the prevention and treatment of the graft versus host disease induced by donor lymphocyte infusion which comprises performing, in a patient to be treated for the prevention and treatment of the graft versus host disease, radiation treatment, infusion of lymphocytes derived from the host or a third party identical in HLA type to the host and intra bone marrow-bone marrow transplantation using bone marrow cells derived from the host or a third party identical in HLA type to the host.
Dependencies are inferred from the claim text.